RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Soochow University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFirst Affiliated Hospital of Soochow University苏州大学附属第一医院SuzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07372352, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Hematological parameters: HB ≥ 70 g/L, PLT ≥ 50 × 10\^9/L, NE ≥ 1.0 × 10\^9/L (Note: Patients who have not received transfusions or drugs to support NE, PLT, or HB increase within 1 week before screening are eligible. Patients with bone marrow involvement by lymphoma resulting in cytopenia are not restricted by this criterion).

    Inclusion criterion 6

  3. Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2.

    Inclusion criterion 3

  4. Creatinine ≤ 132 umol/L or creatinine clearance ≥ 60 ml/min.

    Inclusion criterion 8

    ALT and AST ≤ 3 times the upper limit of normal.

    Inclusion criterion 9

  5. Presence of measurable target lesions [Note: Target lesions are defined as lesions with at least one longest diameter (LD) measurement > 1.5 cm and longest perpendicular diameter (LPD) measurement ≥ 1.0 cm, as assessed by computed tomography (CT) or magnetic resonance imaging (MRI). A maximum of six target lesions can be selected].

    Inclusion criterion 4

  6. Currently suffering from or having had other malignancies within 3 years before enrollment, except for cured basal or squamous cell carcinoma of the skin, superficial bladder cancer, prostatic intraepithelial neoplasia, and cervical carcinoma in situ.

    Exclusion criterion 2

  7. Women of childbearing potential must have a negative pregnancy test. Both male and female patients must agree to use effective contraception during treatment and for 1 year thereafter.

    Inclusion criterion 10

    Pregnant or breastfeeding women.

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07372352, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Relapsed or refractory peripheral T-cell lymphoma after first-line or higher treatment.
  • Age ≥ 18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2.
  • Presence of measurable target lesions [Note: Target lesions are defined as lesions with at least one longest diameter (LD) measurement > 1.5 cm and longest perpendicular diameter (LPD) measurement ≥ 1.0 cm, as assessed by computed tomography (CT) or magnetic resonance imaging (MRI). A maximum of six target lesions can be selected].
  • Adequate function of major organs must meet the following criteria:
  • Hematological parameters: HB ≥ 70 g/L, PLT ≥ 50 × 10\^9/L, NE ≥ 1.0 × 10\^9/L (Note: Patients who have not received transfusions or drugs to support NE, PLT, or HB increase within 1 week before screening are eligible. Patients with bone marrow involvement by lymphoma resulting in cytopenia are not restricted by this criterion).
  • Echocardiographic left ventricular ejection fraction ≥ 50%.
  • Creatinine ≤ 132 umol/L or creatinine clearance ≥ 60 ml/min.
  • ALT and AST ≤ 3 times the upper limit of normal.
  • Women of childbearing potential must have a negative pregnancy test. Both male and female patients must agree to use effective contraception during treatment and for 1 year thereafter.
  • Life expectancy of more than 3 months.
  • Voluntary signed informed consent form.

Exclusion Criteria:

  • Underwent major surgery or severe trauma within 2 weeks before enrollment, or significant adverse effects have not yet recovered.
  • Currently suffering from or having had other malignancies within 3 years before enrollment, except for cured basal or squamous cell carcinoma of the skin, superficial bladder cancer, prostatic intraepithelial neoplasia, and cervical carcinoma in situ.
  • History of stroke or intracranial hemorrhage within the past 3 months.
  • Presence of complications or medical conditions that may interfere with the conduct of the study or pose a significant risk to the patient, including but not limited to severe cardiovascular diseases (e.g., cardiac disease classified as New York Heart Association class III or IV, myocardial infarction within the past 6 months, unstable arrhythmias, or unstable angina) and/or severe pulmonary diseases (e.g., severe obstructive pulmonary disease and history of symptomatic bronchospasm).
  • Human immunodeficiency virus infection, or presence of uncontrollable active hepatitis C virus or hepatitis B virus infection.
  • Uncontrollable active infection.
  • Pregnant or breastfeeding women.
  • Any life-threatening disease, medical condition, or organ system dysfunction that may endanger the safety of the patient, as determined by the investigator.
  • Any condition that may interfere with the absorption or metabolism of zemtovistat, azacitidine, or doneda, or place the study results at unnecessary risk.
  • Lymphoma involvement of the central nervous system.
  • Presence of conditions judged by the investigator to interfere with full participation in the study; conditions posing significant risk to the subject; or conditions that may interfere with the interpretation of study data.

Quoted from ClinicalTrials.gov, NCT07372352, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07372352, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07372352